Ibuprofen Lysine

CHEMBL1201141 Phase 4 معتمد Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
352.5 g/mol
LogP
Phase
4

This is the lysine salt form of ibuprofen, which may dissolve more quickly than standard ibuprofen, potentially providing faster onset of pain relief. The lysine conjugate improves the solubility of ibuprofen for certain formulations, including intravenous use for closing patent ductus arteriosus in premature infants. It shares the anti-inflammatory, analgesic, and antipyretic properties of ibuprofen.

الوزن الجزيئي

352,5000 g/mol

TPSA

127,00 Ų

المجالات العلاجية

آلية العمل

Non-selective COX inhibitor reducing prostaglandin synthesis.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

الآلية

Non-selective COX inhibitor reducing prostaglandin synthesis.

البنية ثنائية الأبعاد

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CC(C)Cc1ccc(C(C)C(=O)O)cc1.NCCCC[C@H](N)C(=O)O

InChI

InChI=1S/C13H18O2.C6H14N2O2/c1-9(2)8-11-4-6-12(7-5-11)10(3)13(14)15;7-4-2-1-3-5(8)6(9)10/h4-7,9-10H,8H2,1-3H3,(H,14,15);5H,1-4,7-8H2,(H,9,10)/t;5-/m.0/s1

Molecular Formula

C19H32N2O4

HBD / HBA

4 / 6

الروابط القابلة للدوران

9

الذرات الثقيلة

25

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

الأسئلة الشائعة

This is the lysine salt form of ibuprofen, which may dissolve more quickly than standard ibuprofen, potentially providing faster onset of pain relief. The lysine conjugate improves the solubility of ibuprofen for certain formulations, including intravenous use for closing patent ductus arteriosus in premature infants. It shares the anti-inflammatory, analgesic, and antipyretic properties of ibuprofen.

Non-selective COX inhibitor reducing prostaglandin synthesis.

Yes, Ibuprofen Lysine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1201141. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 9841440. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

إخلاء المسؤولية الطبية

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.